Sagimet Biosciences Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Sagimet Biosciences Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial positions and corporate history.</b>

AI Summary

Sagimet Biosciences Inc. (SGMT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Sagimet Biosciences Inc. filed a 10-Q for the period ending March 31, 2024. The company's fiscal year ends on December 31. Sagimet Biosciences Inc. was formerly known as 3-V Biosciences, Inc. The company's business address is 155 Bovet Rd., Suite 303, San Mateo, CA 94402. The filing includes data related to common stock, retained earnings, and additional paid-in capital as of March 31, 2024.

Why It Matters

For investors and stakeholders tracking Sagimet Biosciences Inc., this filing contains several important signals. This 10-Q filing provides an update on Sagimet Biosciences Inc.'s financial health and operational status for the first quarter of 2024, crucial for investors assessing the company's performance and future prospects. Understanding the details within this filing, such as changes in equity and historical corporate information, is essential for stakeholders to make informed investment decisions regarding Sagimet Biosciences Inc.

Risk Assessment

Risk Level: low — Sagimet Biosciences Inc. shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial updates without immediate indicators of significant risk or opportunity.

Analyst Insight

Review the detailed financial statements and disclosures in the 10-Q to understand Sagimet Biosciences Inc.'s current financial position and any potential risks or opportunities.

Key Numbers

• 2024-03-31 — Period of Report (10-Q filing date)
• 2024-05-15 — Filed As Of Date (10-Q filing date)
• 12-31 — Fiscal Year End (Company fiscal year)
• 001-41742 — SEC File Number (Company SEC registration)

Key Players & Entities

• Sagimet Biosciences Inc. (company) — Filer name
• 3-V Biosciences, Inc. (company) — Former company name
• 2024-03-31 (date) — Period of report
• 2024-05-15 (date) — Filed as of date
• 155 Bovet Rd., Suite 303 (address) — Business address street
• San Mateo (location) — Business address city
• CA (location) — Business address state
• 94402 (postal_code) — Business address zip

FAQ

Industry Context

Sagimet Biosciences Inc. operates in the pharmaceutical preparations industry, focusing on the development of therapeutics.

Regulatory Implications

The filing is a standard 10-Q, adhering to SEC regulations for quarterly financial reporting by public companies.

What Investors Should Do

1. Analyze the balance sheet and income statement for Q1 2024.
2. Review any new disclosures or risk factors mentioned in the filing.
3. Compare current quarter results to previous periods if comparative data is available.

Key Dates

• 2024-03-31: Period End Date — End of the reporting quarter for the 10-Q filing.
• 2024-05-15: Filing Date — Date the 10-Q was officially filed with the SEC.

Year-Over-Year Comparison

This filing represents the first 10-Q for the fiscal year 2024, providing an update from the previous 10-K filing.

Key Financial Figures

• $0.0001 — ch registered Series A Common Stock, $0.0001 par value per share SGMT Nasdaq Glo

Filing Documents

• sgmt-20240331x10q.htm (10-Q) — 1029KB
• sgmt-20240331xex31d1.htm (EX-31.1) — 12KB
• sgmt-20240331xex31d2.htm (EX-31.2) — 13KB
• sgmt-20240331xex32d1.htm (EX-32.1) — 9KB
• 0001558370-24-008205.txt (&nbsp;) — 4783KB
• sgmt-20240331.xsd (EX-101.SCH) — 24KB
• sgmt-20240331_cal.xml (EX-101.CAL) — 31KB
• sgmt-20240331_def.xml (EX-101.DEF) — 141KB
• sgmt-20240331_lab.xml (EX-101.LAB) — 291KB
• sgmt-20240331_pre.xml (EX-101.PRE) — 229KB
• sgmt-20240331x10q_htm.xml (XML) — 845KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Page Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Balance Sheets 5 Condensed Statements of Operations and Comprehensive Loss 6 Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) 7 Condensed Statements of Cash Flows 8 Notes to Condensed Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 27

Signatures

Signatures 28 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) . All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about: our financial performance; our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements; the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; the scope, progress, results and costs of developing denifanstat or any other drug

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) SAGIMET BIOSCIENCES INC. CONDENSED BALANCE SHEETS (Unaudited) (in thousands, except for share and per share amounts) As of March 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 176,777 $ 75,139 Marketable securities 16,928 19,758 Prepaid expenses and other current assets 786 1,749 Total current assets 194,491 96,646 Operating lease right-of-use assets 37 73 Total assets $ 194,528 $ 96,719 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 531 $ 186 Accrued expenses and other current liabilities (includes $ 96 and $ 31 payable to related parties as of March 31, 2024 and December 31, 2023, respectively) 3,953 5,403 Operating lease liabilities 26 65 Total liabilities 4,510 5,654 Commitments and contingencies (Note 7) Stockholders' equity, $ 0.0001 par value: Undesignated preferred stock, $ 0.0001 per share: 10,000,000 shares authorized; No shares issued and outstanding — — Series A common stock, $ 0.0001 per share: 500,000,000 shares authorized ; 30,393,397 and 21,375,402 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 3 2 Series B common stock, $ 0.0001 per share: 15,000,000 shares authorized; 1,520,490 shares issued and outstanding at each of March 31, 2024 and December 31, 2023 — — Additional paid-in capital 446,381 340,777 Accumulated deficit ( 256,373 ) ( 249,744 ) Accumulated other comprehensive income 7 30 Total stockholders' equity 190,018 91,065 Total liabilities and stockholders' equity $ 194,528 $ 96,719 The accompanying notes are an integral part of these unaudited condensed financial statements. 5 Table of Contents SAGIMET BIOSCIENCES INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except for share and per share amounts) Three Months Ended March 31, 20

View Full Filing

View this 10-Q filing on SEC EDGAR